• 00:00 1.
    index 1
  • 14:20 2.
    A microRNA-21–mediated SATB1/S100A9/NF-kBaxis promotes chronic obstructive pulmonarydisease pathogenesis
  • 14:47 3.
    Slide 2
  • 15:54 4.
    Classification of severity in COPD
  • 16:32 5.
    The pulmonary function parameter
  • 16:32 6.
    The Lung Function Test
  • 16:33 7.
    The pulmonary function parameter
  • 16:33 8.
    Classification of severity in COPD
  • 16:38 9.
    The pulmonary function parameter
  • 22:17 10.
    The Lung Function Test
  • 23:00 11.
    White blood cells participates in airway inflammation
  • 23:56 12.
    So, why the author chose miR-21 as a target gene?
  • 24:23 13.
    CS induces lung miR-21 expression in COPD
  • 26:34 14.
    miR-21 positive signals in the airway epithium
  • 26:36 15.
    CS induces lung miR-21 expression in COPD
  • 31:56 16.
    miR-21 positive signals in the airway epithium
  • 43:43 17.
    Correlation between miR-21 expression and disease severity in COPD.
  • 53:44 18.
    miR-21 expression in different phase of COPD
  • 54:15 19.
    Summary
  • 54:43 20.
    Inhibition of miR-21 suppresses airway inflammation.
  • 1:02:59 21.
    The effectiveness of Ant-21 treatment in COPD
  • 1:04:44 22.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:06:31 23.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:09:50 24.
    Summary
  • 1:10:14 25.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:10:15 26.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:10:31 27.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:10:32 28.
    Summary
  • 1:10:32 29.
    miR-21 reduces SATB1 responses
  • 1:10:33 30.
    Summary
  • 1:10:34 31.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:10:34 32.
    Summary
  • 1:10:37 33.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:10:38 34.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:12:14 35.
    Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
  • 1:12:14 36.
    Summary
  • 1:12:15 37.
    miR-21 reduces SATB1 responses
  • 1:13:08 38.
    miR-21 reduces SATB1 responses
  • 1:13:45 39.
    SATB1-siRNA abrogates Ant-21 treatment effect
  • 1:19:53 40.
    Summary
  • 1:20:16 41.
    miR-21 promotes lung S100A9 expression and NF-kB activity
  • 1:24:29 42.
    The response of SABT1 and S100A9 in COPD progression
  • 1:24:30 43.
    miR-21 promotes lung S100A9 expression and NF-kB activity
  • 1:24:33 44.
    The response of SABT1 and S100A9 in COPD progression
  • 1:27:45 45.
    The correlation of SABT1 and S1009A
  • 1:28:10 46.
    Healthy vs. COPD & Scr vs. Ant Treatment
  • 1:30:26 47.
    Features of disease progression in COPD
  • 1:32:23 48.
    Conclusion
  • Index
  • Notes
  • Comment
  • Fullscreen
20231127 lab meeting_庭汶
Duration: 1:35:40, Browse: 144, Last Updated: 2023-11-27
    • 00:00 1.
      index 1
    • 14:20 2.
      A microRNA-21–mediated SATB1/S100A9/NF-kBaxis promotes chronic obstructive pulmonarydisease pathogenesis
    • 14:47 3.
      Slide 2
    • 15:54 4.
      Classification of severity in COPD
    • 16:32 5.
      The pulmonary function parameter
    • 16:32 6.
      The Lung Function Test
    • 16:33 7.
      The pulmonary function parameter
    • 16:33 8.
      Classification of severity in COPD
    • 16:38 9.
      The pulmonary function parameter
    • 22:17 10.
      The Lung Function Test
    • 23:00 11.
      White blood cells participates in airway inflammation
    • 23:56 12.
      So, why the author chose miR-21 as a target gene?
    • 24:23 13.
      CS induces lung miR-21 expression in COPD
    • 26:34 14.
      miR-21 positive signals in the airway epithium
    • 26:36 15.
      CS induces lung miR-21 expression in COPD
    • 31:56 16.
      miR-21 positive signals in the airway epithium
    • 43:43 17.
      Correlation between miR-21 expression and disease severity in COPD.
    • 53:44 18.
      miR-21 expression in different phase of COPD
    • 54:15 19.
      Summary
    • 54:43 20.
      Inhibition of miR-21 suppresses airway inflammation.
    • 1:02:59 21.
      The effectiveness of Ant-21 treatment in COPD
    • 1:04:44 22.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:06:31 23.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:09:50 24.
      Summary
    • 1:10:14 25.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:10:15 26.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:10:31 27.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:10:32 28.
      Summary
    • 1:10:32 29.
      miR-21 reduces SATB1 responses
    • 1:10:33 30.
      Summary
    • 1:10:34 31.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:10:34 32.
      Summary
    • 1:10:37 33.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:10:38 34.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:12:14 35.
      Inhibition of CS-induced lung miR-21 prevents the impairment of lung function
    • 1:12:14 36.
      Summary
    • 1:12:15 37.
      miR-21 reduces SATB1 responses
    • 1:13:08 38.
      miR-21 reduces SATB1 responses
    • 1:13:45 39.
      SATB1-siRNA abrogates Ant-21 treatment effect
    • 1:19:53 40.
      Summary
    • 1:20:16 41.
      miR-21 promotes lung S100A9 expression and NF-kB activity
    • 1:24:29 42.
      The response of SABT1 and S100A9 in COPD progression
    • 1:24:30 43.
      miR-21 promotes lung S100A9 expression and NF-kB activity
    • 1:24:33 44.
      The response of SABT1 and S100A9 in COPD progression
    • 1:27:45 45.
      The correlation of SABT1 and S1009A
    • 1:28:10 46.
      Healthy vs. COPD & Scr vs. Ant Treatment
    • 1:30:26 47.
      Features of disease progression in COPD
    • 1:32:23 48.
      Conclusion
    Location
    Folder name
    2023
    Author
    周楷軒
    Branch
    賴亮全教授
    Created
    2023-11-27 12:29:34
    Last Updated
    2023-11-27 12:55:40
    Duration
    1:35:40